Form 8-K - Current report:
SEC Accession No. 0001558370-22-013802
Filing Date
2022-08-19
Accepted
2022-08-19 07:08:44
Documents
15
Period of Report
2022-08-18
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20220818x8k.htm   iXBRL 8-K 51679
2 EX-3.2 kala-20220818xex3d2.htm EX-3.2 7992
3 EX-99.1 kala-20220818xex99d1.htm EX-99.1 11747
4 GRAPHIC kala-20220818xex99d1001.jpg GRAPHIC 8886
  Complete submission text file 0001558370-22-013802.txt   218532

Data Files

Seq Description Document Type Size
5 EX-101.SCH kala-20220818.xsd EX-101.SCH 3134
6 EX-101.LAB kala-20220818_lab.xml EX-101.LAB 16579
7 EX-101.PRE kala-20220818_pre.xml EX-101.PRE 10522
9 EXTRACTED XBRL INSTANCE DOCUMENT kala-20220818x8k_htm.xml XML 5058
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 221178929
SIC: 2834 Pharmaceutical Preparations